Technology Partners

Technology Partners is a venture capital firm founded in 1980 and headquartered in Novato, California. The firm specializes in seed, early, and later-stage investments, focusing primarily on companies in the clean technology and life science sectors. With decades of experience, Technology Partners seeks to support innovative businesses that address critical challenges within these industries.

van den Berg, Marc

General Partner

82 past transactions

Benvenue Medical

Series F in 2016
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Elcelyx Therapeutics

Series E in 2015
Elcelyx Therapeutics, founded in 2010 and headquartered in San Diego, California, focuses on developing innovative treatments for diabetes and obesity-related metabolic disorders through its proprietary Gut Sensory Modulation (GSM) technology. The company's lead product candidate, NewMet, is designed to improve glucose metabolism by amplifying hormone release in the lower gut, thereby addressing significant unmet needs in the oral anti-diabetic market. Currently entering Phase 2b development, NewMet represents a potential breakthrough in diabetes management. Elcelyx also offers Lovidia, which targets similar metabolic issues without causing systemic side effects. The company is supported by a skilled management team, experienced investors, and a network of scientists and clinicians. In 2013, Elcelyx established NaZura BioHealth Inc. to focus on developing additional non-NewMet assets, further expanding its research and product pipeline.

Beamreach

Series D in 2015
Beamreach Solar focuses on the development of high-efficiency, low-cost crystalline silicon solar cells and modules for photovoltaic electricity generation. The company utilizes an innovative, proprietary cell architecture to enhance the sunlight capture and conversion efficiency of mono-crystalline silicon materials. This approach not only improves the performance of their solar panels but also aims to make clean energy more affordable and accessible. By optimizing the design, Beamreach enables solar installers and commercial building owners to reduce installation time and labor costs associated with traditional solar panels and racking systems.

Kaiam

Venture Round in 2014
Kaiam is a manufacturer of optical components focused on high-speed data transfer for data centers. The company specializes in the production of photonic integrated circuits, planar light wave circuits, optical sub-assemblies, modules, and transceivers, catering to various applications in the fiber optics communications industry. By delivering quality optical networking products, Kaiam aims to enhance data transmission capabilities for its clients.

Beamreach

Series D in 2014
Beamreach Solar focuses on the development of high-efficiency, low-cost crystalline silicon solar cells and modules for photovoltaic electricity generation. The company utilizes an innovative, proprietary cell architecture to enhance the sunlight capture and conversion efficiency of mono-crystalline silicon materials. This approach not only improves the performance of their solar panels but also aims to make clean energy more affordable and accessible. By optimizing the design, Beamreach enables solar installers and commercial building owners to reduce installation time and labor costs associated with traditional solar panels and racking systems.

Benvenue Medical

Series E in 2014
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

ForSight Labs

Series C in 2014
ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

ForSight VISION5

Series C in 2014
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

Transcend Medical

Series C in 2014
Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015. In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.

Elcelyx Therapeutics

Series C in 2014
Elcelyx Therapeutics, founded in 2010 and headquartered in San Diego, California, focuses on developing innovative treatments for diabetes and obesity-related metabolic disorders through its proprietary Gut Sensory Modulation (GSM) technology. The company's lead product candidate, NewMet, is designed to improve glucose metabolism by amplifying hormone release in the lower gut, thereby addressing significant unmet needs in the oral anti-diabetic market. Currently entering Phase 2b development, NewMet represents a potential breakthrough in diabetes management. Elcelyx also offers Lovidia, which targets similar metabolic issues without causing systemic side effects. The company is supported by a skilled management team, experienced investors, and a network of scientists and clinicians. In 2013, Elcelyx established NaZura BioHealth Inc. to focus on developing additional non-NewMet assets, further expanding its research and product pipeline.

Kaiam

Venture Round in 2013
Kaiam is a manufacturer of optical components focused on high-speed data transfer for data centers. The company specializes in the production of photonic integrated circuits, planar light wave circuits, optical sub-assemblies, modules, and transceivers, catering to various applications in the fiber optics communications industry. By delivering quality optical networking products, Kaiam aims to enhance data transmission capabilities for its clients.

Beamreach

Series C in 2013
Beamreach Solar focuses on the development of high-efficiency, low-cost crystalline silicon solar cells and modules for photovoltaic electricity generation. The company utilizes an innovative, proprietary cell architecture to enhance the sunlight capture and conversion efficiency of mono-crystalline silicon materials. This approach not only improves the performance of their solar panels but also aims to make clean energy more affordable and accessible. By optimizing the design, Beamreach enables solar installers and commercial building owners to reduce installation time and labor costs associated with traditional solar panels and racking systems.

CoalTek

Convertible Note in 2013
CoalTek's technology reduces moisture content in a broad range of coals, optimizing plant efficiency and delivering environmental integrity. The CoalTek process was developed, tested, and proven over eight years by Dr. Jerry Weinberg, the company's co-founder, along with chief geologist Neil Ginther. CoalTek opened its first commercial processing facility in Calvert City, Kentucky in 2006. The plant's initial capacity of 120,000 tons/yr will be expanded in the future, and there are also plans to build additional facilities, to meet the growing demand for clean coal.

ForSight Labs

Series B in 2013
ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

ForSight VISION5

Series B in 2013
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

Scioderm

Series A in 2013
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and licensing of small molecules and biologics aimed at treating and preventing human diseases. The company primarily focuses on two portfolios: immunology and central nervous system (CNS) disorders. Its immunology pipeline includes vaccines and biologics for infectious diseases, cancer, and autoimmune conditions, with lead candidates such as TNX-1800, a vaccine for COVID-19, and TNX-1500, a monoclonal antibody targeting organ transplant rejection. In the CNS portfolio, Tonix is developing treatments for pain, neurologic, psychiatric, and addiction disorders, including TNX-102 SL for fibromyalgia and TNX-1900, an intranasal oxytocin for migraine. The company's preclinical pipeline also includes promising candidates for conditions like posttraumatic stress disorder and cancer. Founded in 2007 and headquartered in New York, Tonix aims to alleviate suffering through innovative therapeutic solutions.

TRIA Beauty

Venture Round in 2012
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

Akros Silicon

Venture Round in 2012
Akros Silicon Inc. is a fabless semiconductor company that specializes in developing power management integrated circuits (ICs) aimed at enhancing energy management applications. Utilizing precision analog and mixed-signal CMOS-based technologies, the company focuses on creating system-level solutions that support remote and intelligent network-based energy management. Its product offerings include isolated DC-DC system-on-a-chip solutions, power-over-Ethernet powered device ICs, digital isolators, and various intelligent energy management ICs. These products are employed in a wide range of applications, such as Ethernet switches, routers, programmable logic controllers, solar microinverters, VoIP phones, and industrial equipment. Founded in 2005, Akros Silicon is headquartered in San Jose, California, with an additional office in Shanghai, China. The company operates as a subsidiary of Kinetic Technologies HK Limited.

Elcelyx Therapeutics

Series B in 2012
Elcelyx Therapeutics, founded in 2010 and headquartered in San Diego, California, focuses on developing innovative treatments for diabetes and obesity-related metabolic disorders through its proprietary Gut Sensory Modulation (GSM) technology. The company's lead product candidate, NewMet, is designed to improve glucose metabolism by amplifying hormone release in the lower gut, thereby addressing significant unmet needs in the oral anti-diabetic market. Currently entering Phase 2b development, NewMet represents a potential breakthrough in diabetes management. Elcelyx also offers Lovidia, which targets similar metabolic issues without causing systemic side effects. The company is supported by a skilled management team, experienced investors, and a network of scientists and clinicians. In 2013, Elcelyx established NaZura BioHealth Inc. to focus on developing additional non-NewMet assets, further expanding its research and product pipeline.

Beamreach

Series C in 2012
Beamreach Solar focuses on the development of high-efficiency, low-cost crystalline silicon solar cells and modules for photovoltaic electricity generation. The company utilizes an innovative, proprietary cell architecture to enhance the sunlight capture and conversion efficiency of mono-crystalline silicon materials. This approach not only improves the performance of their solar panels but also aims to make clean energy more affordable and accessible. By optimizing the design, Beamreach enables solar installers and commercial building owners to reduce installation time and labor costs associated with traditional solar panels and racking systems.

Benvenue Medical

Series D in 2012
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Beamreach

Series C in 2012
Beamreach Solar focuses on the development of high-efficiency, low-cost crystalline silicon solar cells and modules for photovoltaic electricity generation. The company utilizes an innovative, proprietary cell architecture to enhance the sunlight capture and conversion efficiency of mono-crystalline silicon materials. This approach not only improves the performance of their solar panels but also aims to make clean energy more affordable and accessible. By optimizing the design, Beamreach enables solar installers and commercial building owners to reduce installation time and labor costs associated with traditional solar panels and racking systems.

Transcend Medical

Series B in 2012
Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015. In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.

Medley Health

Series A in 2011
Medley Health is an innovative, entrepreneurial, technology-driven company. It's backed by top-tier investors and a management team with deep business expertise in healthcare, Internet and web services, as well as next-generation communications technologies.

Transcend Medical

Series B in 2011
Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015. In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.

Revance Therapeutics

Series D in 2011
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Benvenue Medical

Series C in 2011
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Alta Devices

Private Equity Round in 2011
Alta Devices, Inc. is a manufacturer of single junction solar technology, specializing in thin and flexible mobile power solutions. Founded in 2007 and based in Sunnyvale, California, the company serves various applications, including unmanned systems, consumer electronics, sensors, automotive, remote exploration, wearables, and the Internet of Things. Alta Devices aims to enhance the production economics of high-efficiency solar photovoltaic applications. As a development stage company, it has garnered venture capital support from notable investors. Since February 2015, it has operated as a subsidiary of Hanergy Hi-Tech Power (HK) Limited.

TRIA Beauty

Venture Round in 2011
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

Incline Therapeutics

Series A in 2010
Incline Therapeutics is a privately-held, hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system). Incline is financed by leading life science venture capital firms and led by a management team with significant pharmaceutical and medical device industry experience.

Revance Therapeutics

Series D in 2009
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

EmSense

Series C in 2009
EmSense Corporation provides scalable physiological and brainwave measurement technology. Its EmSense headset measures brainwave cognition and emotion on a moment by moment basis as consumers are exposed to advertising, video games, political messaging, movies, and TV shows, as well as incorporates physiological sensors that measure viewers' blinking, breathing, and physical motion to their heart activity and moments when they blush. The company was founded in 2004 and is based in San Francisco, California with additional offices in Monterey and Santa Monica, California.

Transcend Medical

Series B in 2009
Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015. In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.

Visiogen

Series D in 2009
Visiogen, Inc. is an ophthalmic medical device company focused on developing innovative vision solutions for patients with cataracts, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless range of near, intermediate, and distance vision without the need for glasses or contact lenses. This advanced device is supplied in a pre-loaded injector to minimize lens handling during surgical procedures. Visiogen's technology has received CE Mark approval in Europe and is currently in clinical trials in the United States, aiming to enhance the quality of life for cataract patients through improved vision correction options.

PowerGenix

Funding Round in 2008
PowerGenix specializes in the manufacturing of nickel-zinc rechargeable batteries designed for mission-critical applications. Their products are utilized in various sectors, including data centers, intelligent transportation, cordless power tools, hybrid electric vehicles, uninterruptible power supply (UPS) systems, personal mobility devices, and medical devices. By focusing on sustainable solutions, PowerGenix aims to provide efficient and reliable battery technologies that support diverse industries while promoting environmental responsibility.

Abound Solar

Venture Round in 2008
Abound Solar produces next-generation, thin film photovoltaic modules intended to deliver the lowest levelized cost of electricity.

Beamreach

Series B in 2008
Beamreach Solar focuses on the development of high-efficiency, low-cost crystalline silicon solar cells and modules for photovoltaic electricity generation. The company utilizes an innovative, proprietary cell architecture to enhance the sunlight capture and conversion efficiency of mono-crystalline silicon materials. This approach not only improves the performance of their solar panels but also aims to make clean energy more affordable and accessible. By optimizing the design, Beamreach enables solar installers and commercial building owners to reduce installation time and labor costs associated with traditional solar panels and racking systems.

BrainCells

Series B in 2008
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Revance Therapeutics

Series C in 2007
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Imperium Renewables

Series B in 2007
Imperium Renewables, Inc. is a producer and marketer of biodiesel in the United States, utilizing feedstock oils and glycerin, a by-product of the biodiesel production process. The biodiesel produced by the company serves as an alternative fuel for various modes of transportation, including cars, trucks, ships, trains, and planes. Imperium Renewables operates BQ-9000-certified biodiesel facilities located in Hoquiam, Washington, and Oahu, Hawaii. Established in 2004 and originally named Seattle Biodiesel, the company rebranded to its current name in May 2005 and markets its products through a network of distributors across the country.

ITM Software

Venture Round in 2007
ITM Software specializes in IT Business Management, offering a comprehensive integrated solution designed to enhance visibility, coordination, and control across various IT functions. The company's core product, the ITM Business Suite, consists of six components that address key areas such as human resources, vendor management, asset management, financials, projects, and regulatory compliance. By bridging traditional silos within IT, ITM Software promotes increased transparency and more effective decision-making, ultimately aligning IT operations with broader business objectives. Founded in 2001 by former CIOs, the company leverages its leadership team's extensive experience and a skilled software development group to deliver both software products and best-practice expertise. ITM Software serves a diverse clientele, including Fortune 2000 companies, government agencies, and educational institutions, and is headquartered in Mountain View, California.

Leptos Biomedical

Series C in 2007
Leptos Biomedical specializes in a proprietary neuromodulation therapy aimed at treating chronic obesity. Established in 2002 and located in Fridley, Minnesota, the company utilizes a pacemaker-like device to electrically activate a specific nerve within the autonomic nervous system, thereby addressing obesity at a neurological level. This innovative approach seeks to offer an alternative treatment option for individuals struggling with weight management.

TRIA Beauty

Series D in 2007
TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

Tesla

Series D in 2007
Tesla, Inc. designs, develops, manufactures, and sells electric vehicles and energy generation and storage systems globally, with a significant presence in the United States, China, the Netherlands, and Norway. The company operates in two main segments: Automotive and Energy Generation and Storage. The Automotive segment includes a range of vehicles, such as luxury and midsize sedans, crossover SUVs, and light trucks, alongside electric powertrain components and services. Tesla markets its vehicles through company-owned showrooms and its website. The Energy Generation and Storage segment offers lithium-ion battery systems for residential and commercial use, as well as solar energy products, including solar panels and solar roofs. Additionally, Tesla provides vehicle insurance and operates a fast-charging network. Founded in 2003 and headquartered in Palo Alto, California, Tesla aims to accelerate the transition to sustainable energy and mobility.

Nfocus Neuromedical

Series B in 2007
Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

Accelergy

Series B in 2006
Accelergy Corporation specializes in the production of low carbon synthetic distillate liquids and transportation fuels, catering to energy and specialty product markets on a global scale. Founded in 2003 and based in Houston, Texas, the company utilizes its proprietary Hydroconversion to X (HDX) technologies to convert natural gas, biomass, and coal into clean products, including solvents, lubricants, performance fluids, and fuels. By leveraging domestic, carbon-based resources, Accelergy offers cost-competitive alternatives that significantly reduce carbon footprints compared to traditional petroleum products. The company's innovative approach eliminates the need for costly infrastructure often associated with other synthetic fuel technologies. In addition to its core production capabilities, Accelergy has established a strategic alliance with Owensboro Grain LLC, enhancing its position in the market.

PowerGenix

Series C in 2006
PowerGenix specializes in the manufacturing of nickel-zinc rechargeable batteries designed for mission-critical applications. Their products are utilized in various sectors, including data centers, intelligent transportation, cordless power tools, hybrid electric vehicles, uninterruptible power supply (UPS) systems, personal mobility devices, and medical devices. By focusing on sustainable solutions, PowerGenix aims to provide efficient and reliable battery technologies that support diverse industries while promoting environmental responsibility.

CoalTek

Series B in 2006
CoalTek's technology reduces moisture content in a broad range of coals, optimizing plant efficiency and delivering environmental integrity. The CoalTek process was developed, tested, and proven over eight years by Dr. Jerry Weinberg, the company's co-founder, along with chief geologist Neil Ginther. CoalTek opened its first commercial processing facility in Calvert City, Kentucky in 2006. The plant's initial capacity of 120,000 tons/yr will be expanded in the future, and there are also plans to build additional facilities, to meet the growing demand for clean coal.

BioTrove

Venture Round in 2006
BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

NanoGram

Venture Round in 2006
NanoGram Corporation is a nanotechnology company focused on developing and manufacturing advanced products for photovoltaics, electronics, and displays. It offers a customized application-specific nanotechnology platform that produces nanoscale compositions for various sectors, including optical, electronic, imaging, biomedical, and energy applications. The company has successfully incubated and spun out two firms, NeoPhotonics and NanoGram Devices. With a presence in Japan through its Tokyo office and a strategic partnership with Nagase & Co., Ltd / Nagase ChemteX Corporation, NanoGram is expanding its footprint in the region. Additionally, its office in Seoul, South Korea, supports its growth in the Korean market.

eNeura Therapeutics

Series B in 2005
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.

Sensicore

Series C in 2005
Sensicore, Inc., based in Ann Arbor, Michigan, specializes in developing smart sensor systems and sensor networks for automated water testing, data collection, and analysis in both drinking and industrial applications. The company provides a range of products including WaterPOINT, a handheld device that offers various chemistry measurements for on-site testing, and WaterNOW, a web-based platform for data visualization and management. Additionally, Sensicore offers sensor kits and bundles for disinfection and basic water testing, as well as colorimetric test kits for a variety of water quality parameters. Their offerings are designed to support municipalities and industries in monitoring and managing water quality effectively. Founded in 2000, Sensicore operates as a subsidiary of GE Analytical Instruments, Inc.

CoalTek

Series A in 2005
CoalTek's technology reduces moisture content in a broad range of coals, optimizing plant efficiency and delivering environmental integrity. The CoalTek process was developed, tested, and proven over eight years by Dr. Jerry Weinberg, the company's co-founder, along with chief geologist Neil Ginther. CoalTek opened its first commercial processing facility in Calvert City, Kentucky in 2006. The plant's initial capacity of 120,000 tons/yr will be expanded in the future, and there are also plans to build additional facilities, to meet the growing demand for clean coal.

ITM Software

Venture Round in 2005
ITM Software specializes in IT Business Management, offering a comprehensive integrated solution designed to enhance visibility, coordination, and control across various IT functions. The company's core product, the ITM Business Suite, consists of six components that address key areas such as human resources, vendor management, asset management, financials, projects, and regulatory compliance. By bridging traditional silos within IT, ITM Software promotes increased transparency and more effective decision-making, ultimately aligning IT operations with broader business objectives. Founded in 2001 by former CIOs, the company leverages its leadership team's extensive experience and a skilled software development group to deliver both software products and best-practice expertise. ITM Software serves a diverse clientele, including Fortune 2000 companies, government agencies, and educational institutions, and is headquartered in Mountain View, California.

NeuroPace

Venture Round in 2005
NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

PolyFuel

Series C in 2004
PolyFuel has develops improved membranes and systems for resolving the power gap in portable electronic devices.

Revance Therapeutics

Series B in 2004
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Accelergy

Series A in 2004
Accelergy Corporation specializes in the production of low carbon synthetic distillate liquids and transportation fuels, catering to energy and specialty product markets on a global scale. Founded in 2003 and based in Houston, Texas, the company utilizes its proprietary Hydroconversion to X (HDX) technologies to convert natural gas, biomass, and coal into clean products, including solvents, lubricants, performance fluids, and fuels. By leveraging domestic, carbon-based resources, Accelergy offers cost-competitive alternatives that significantly reduce carbon footprints compared to traditional petroleum products. The company's innovative approach eliminates the need for costly infrastructure often associated with other synthetic fuel technologies. In addition to its core production capabilities, Accelergy has established a strategic alliance with Owensboro Grain LLC, enhancing its position in the market.

Saegis Pharmaceuticals

Series B in 2003
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

ITM Software

Series B in 2003
ITM Software specializes in IT Business Management, offering a comprehensive integrated solution designed to enhance visibility, coordination, and control across various IT functions. The company's core product, the ITM Business Suite, consists of six components that address key areas such as human resources, vendor management, asset management, financials, projects, and regulatory compliance. By bridging traditional silos within IT, ITM Software promotes increased transparency and more effective decision-making, ultimately aligning IT operations with broader business objectives. Founded in 2001 by former CIOs, the company leverages its leadership team's extensive experience and a skilled software development group to deliver both software products and best-practice expertise. ITM Software serves a diverse clientele, including Fortune 2000 companies, government agencies, and educational institutions, and is headquartered in Mountain View, California.

Sensicore

Series B in 2003
Sensicore, Inc., based in Ann Arbor, Michigan, specializes in developing smart sensor systems and sensor networks for automated water testing, data collection, and analysis in both drinking and industrial applications. The company provides a range of products including WaterPOINT, a handheld device that offers various chemistry measurements for on-site testing, and WaterNOW, a web-based platform for data visualization and management. Additionally, Sensicore offers sensor kits and bundles for disinfection and basic water testing, as well as colorimetric test kits for a variety of water quality parameters. Their offerings are designed to support municipalities and industries in monitoring and managing water quality effectively. Founded in 2000, Sensicore operates as a subsidiary of GE Analytical Instruments, Inc.

Storability Software

Series D in 2003
Storability Software specializes in enterprise storage resource management solutions designed to simplify and centralize the management of complex, multi-site, and multi-vendor storage infrastructures. Its flagship product, the Global Storage Manager, is an open standards-based solution that empowers customers to better understand, manage, and optimize their storage investments. By utilizing Storability Software's offerings, clients can achieve increased asset utilization, improved management efficiency, enhanced quality of service, and greater availability of their storage resources.

Rinat Neuroscience

Series B in 2003
Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

Iomai

Series C in 2003
Iomai Corporation specializes in the discovery and development of vaccines and immune system stimulants using a unique, needle-free approach known as transcutaneous immunization (TCI). This technology utilizes antigen-presenting cells located in the outer layers of the skin to enhance immune responses, allowing for the improvement of existing vaccines and the creation of new ones that can only be administered through this method. Founded in 1997 and based in Gaithersburg, Maryland, Iomai aims to expand the global vaccine market. Following its acquisition by Intercell Ag, the company was rebranded as Intercell USA, Inc. and now operates as a subsidiary of Intercell Biomedical Research & Development AG.

Datria Systems

Series C in 2002
Datria Systems specializes in voice-enabled enterprise mobility solutions that enhance communication between central offices and field representatives. The company offers configurable software that allows users to exchange real-time information through existing phones, two-way radios, or VoIP-capable devices. By integrating voice technology into business processes, Datria aims to streamline operations and improve efficiency for organizations seeking to optimize their workforce communication.

PolyFuel

Series B in 2002
PolyFuel has develops improved membranes and systems for resolving the power gap in portable electronic devices.

Storability Software

Series C in 2002
Storability Software specializes in enterprise storage resource management solutions designed to simplify and centralize the management of complex, multi-site, and multi-vendor storage infrastructures. Its flagship product, the Global Storage Manager, is an open standards-based solution that empowers customers to better understand, manage, and optimize their storage investments. By utilizing Storability Software's offerings, clients can achieve increased asset utilization, improved management efficiency, enhanced quality of service, and greater availability of their storage resources.

eNeura Therapeutics

Series A in 2002
ENeura Therapeutics is a medical technology company developing transcranial magnetic stimulation devices for the treatment of migraines. It pioneers the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office, or on the go.

NightFire Software

Series D in 2002
NightFire Software offers the first packaged order management software to automate the telecommunications service supply chain. By simplifying the interaction between retailers and wholesalers of telecommunications services, NightFire's products enable telecommunications service providers to deliver services quickly and cost-effectively to the newly deregulated telecommunications market, estimated to be $160 billion in 1998. The NightFire flagship product, NetServ Express automates the entire ordering process for competitive service providers, ensuring the highest level of service at the lowest cost and reducing the management burden on incumbent providers.

Storability Software

Series B in 2001
Storability Software specializes in enterprise storage resource management solutions designed to simplify and centralize the management of complex, multi-site, and multi-vendor storage infrastructures. Its flagship product, the Global Storage Manager, is an open standards-based solution that empowers customers to better understand, manage, and optimize their storage investments. By utilizing Storability Software's offerings, clients can achieve increased asset utilization, improved management efficiency, enhanced quality of service, and greater availability of their storage resources.

Spinal Dynamics

Series B in 2001
Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.

Rinat Neuroscience

Series A in 2001
Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

APX

Series C in 2000
APX, Inc. specializes in providing software solutions tailored for the energy and environmental sectors. The company focuses on infrastructure solutions that support renewable energy and greenhouse gas management, including carbon commodities. Key offerings include the APX Environmental Management Account for asset and risk management, APX Registries for renewable energy certificate management across North America, and a platform for tracking greenhouse gas offsets. Additionally, APX provides demand response systems integrated with independent system operators (ISOs) and a suite of tools under APX MarketSuite to facilitate scheduling, operations, and settlement processes for market participants. Their services include real-time agent support, transaction management, resource control for renewable energy sources, and helpdesk assistance. Founded in 1996 and based in San Jose, California, APX has built a reputation for delivering innovative technology and service solutions, leveraging its extensive industry expertise to meet the evolving needs of its clients.

Encirq Corporation

Venture Round in 2000
Encirq solves marketing's #1 challenge: Delivering Personalization with Privacy™. Encirq is an online marketing services company that has developed a unique data engine to deliver individualized, consumer-centered marketing over the Internet. We use online and offline, real-time individual transactional data in a private and secure environment. Marketers and Encirq cannot see the data. Rather, the data reside on each consumer's personal computer, and filter out marketing messages that are not relevant. The service and technology are extendible to broadband, to other network devices, and eventually can be used to deliver personalized television commercials to individual households. Encirq's data engine does two things: It provides cost-effective access to consumer information not previously available; and it enables personalized real-time marketing programs. We have filed multiple patent applications on Encirq's illumination processes and technology.

APX

Series C in 2000
APX, Inc. specializes in providing software solutions tailored for the energy and environmental sectors. The company focuses on infrastructure solutions that support renewable energy and greenhouse gas management, including carbon commodities. Key offerings include the APX Environmental Management Account for asset and risk management, APX Registries for renewable energy certificate management across North America, and a platform for tracking greenhouse gas offsets. Additionally, APX provides demand response systems integrated with independent system operators (ISOs) and a suite of tools under APX MarketSuite to facilitate scheduling, operations, and settlement processes for market participants. Their services include real-time agent support, transaction management, resource control for renewable energy sources, and helpdesk assistance. Founded in 1996 and based in San Jose, California, APX has built a reputation for delivering innovative technology and service solutions, leveraging its extensive industry expertise to meet the evolving needs of its clients.

SkillsVillage

Series B in 2000
SkillsVillage.com operates as an online recruitment service specializing in information technology professionals. It offers a comprehensive platform that facilitates the procurement of skilled workers throughout the entire hiring process. This platform enables companies to quickly and efficiently identify, hire, and manage contract workers while aggregating staffing suppliers. SkillsVillage's eMarketplace effectively matches available skills with business needs, supported by a robust network of skilled professionals. The company also provides resource management tools, including a unique contractor rating system that integrates with existing corporate infrastructures. Additionally, SkillsVillage offers hosted solutions for skills sourcing, procurement, fulfillment, and supplier network management, streamlining the recruitment and management of contract workers for businesses.

ELoan

Post in 2000
E-LOAN is a nationwide financial services company that specializes in providing consumers with straightforward access to high-yield savings accounts and certificates of deposit (CDs). Established in 1997, the company emphasizes pro-consumer values and aims to enhance the online experience for its customers. In addition to savings products, E-LOAN connects users with several preferred, nationally recognized lending partners, assisting them in finding loans that align with their financial needs. The company also offers educational tools and resources designed to simplify the financial research process for its clients.

Imagicast

Series C in 2000
Imagicast, Inc. specializes in strategic merchandising solutions tailored for retailers. The company offers a one-to-one merchandising platform that integrates marketing, e-commerce, and business intelligence capabilities. This platform enables retailers and brand manufacturers to create engaging in-store product demonstrations and personalized promotions. Additionally, it provides valuable insights into customer shopping and purchasing behaviors, allowing clients to enhance their conversion rates from shoppers to buyers. By focusing on these strategic solutions, Imagicast aims to support retailers in maximizing their sales potential and improving customer engagement.

AllAdvantage

Venture Round in 2000
As of January 2001, AllAdvantage Inc. went out of business. AllAdvantage.com, Inc. operates as an Internet advertising company. It pays its users/members a portion of the advertising revenue generated by their online viewing habits. The company also allows members to receive membership benefits that include sponsor discounts and rebates for surfing the Web. In addition, it provides incentives for advertisers to build one-on-one relationships with its members. The company was founded in 1999 and is based in Hayward, California with additional offices in Atlanta, Boston, Chicago, Dallas, Detroit, Hayward, London, Los Angeles, New York, Paris, Seattle, Sydney, and Washington DC.

HeartStent

Venture Round in 1999
HeartStent is a cardiovascular device firm. It is a direct revascularization device intended for coronary artery disease patients currently treated with coronary artery bypass grafts.

Spinal Dynamics

Series A in 1997
Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.